Furthermore, there was no significant difference in 5-year OS and DFS rates between patients with or without hypermethylation of ADAM19 or MSC in either (MSI+ or EBV+) GC patients or MSI−/EBV− GC patients. This evidence concerns the gene ADAM19 and gastric cancer.